Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale COO and Secretary sold 7,500 shares at an average $18.00 ($135,017)
  2. 4 Open-market sale President and CEO sold 21,268 shares at an average $18.00 ($382,874)
  3. 4 Open-market sale President and CEO sold 43,485 shares at an average $18.02 ($783,574)
  4. 4 Open-market sale COO and Secretary sold 15,000 shares at an average $18.02 ($270,287)
  5. 10-Q Report Quarterly Report
  6. 8-K Event Results of operations
  7. 4 Option exercise COO and Secretary acquired 5,129 shares (option exercise)
  8. UPLOAD Other SEC-generated Letter
  9. CORRESP Other Correspondence Between Filers and SEC Staff
  10. 4 Open-market sale COO and Secretary sold 7,500 shares at $18.16 ($136,200)
  11. 4 Open-market sale President and CEO sold 8,581 shares at an average $18.05 ($154,894)
  12. 4 Shares withheld for taxes COO and Secretary gave up 1,975 shares (to pay taxes)
  13. 4 Shares withheld for taxes Chief Medical Officer gave up 2,834 shares (to pay taxes)
  14. 4 Shares withheld for taxes CFO and Treasurer gave up 1,977 shares (to pay taxes)
  15. UPLOAD Other SEC-generated Letter
  16. 4 Other disposition Director disposed of 400,000 shares (other)
  17. 4 Other disposition 10% owner disposed of 400,000 shares (other)
  18. 4 Open-market sale COO and Secretary sold 7,500 shares at $18.81 ($141,075)
  19. 10-Q Report Quarterly Report
  20. 8-K Event Results of operations

Page 31 of 40 · 789 filings